• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

对《评估人抗SARS-CoV-2康复期血浆对COVID-19重症成人患者的疗效和安全性：一项随机对照试验研究方案的结构化总结》的更正

Correction to: Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: A structured summary of a study protocol for a randomized controlled trial.

作者信息

Eckhardt Christina M, Cummings Matthew J, Rajagopalan Kartik N, Borden Sarah, Bitan Zachary C, Wolf Allison, Kantor Alex, Briese Thomas, Meyer Benjamin J, Jacobson Samuel D, Scotto Dawn, Mishra Nischay, Philip Neena M, Stotler Brie A, Schwartz Joseph, Shaz Beth, Spitalnik Steven L, Eisenberger Andrew, Hod Jessica Justman Eldad A, Cheung Ken, Lipkin W Ian, O'Donnell Max R

机构信息

Columbia University Medical Center, New York, USA.

出版信息

Trials. 2020 Nov 17;21(1):927. doi: 10.1186/s13063-020-04877-z.

DOI:10.1186/s13063-020-04877-z
PMID:33203476
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7670989/
Abstract

An amendment to this paper has been published and can be accessed via the original article.

摘要

本文的一篇修正已发表，可通过原始文章获取。

相似文献

1
Correction to: Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: A structured summary of a study protocol for a randomized controlled trial.对《评估人抗SARS-CoV-2康复期血浆对COVID-19重症成人患者的疗效和安全性：一项随机对照试验研究方案的结构化总结》的更正
Trials. 2020 Nov 17;21(1):927. doi: 10.1186/s13063-020-04877-z.
2
Correction to: Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: A structured summary of a study protocol for a randomized controlled trial.对《评估人抗SARS-CoV-2康复期血浆对COVID-19重症成人患者的疗效和安全性：一项随机对照试验研究方案的结构化总结》的更正
Trials. 2020 Jun 16;21(1):536. doi: 10.1186/s13063-020-04504-x.
3
Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: A structured summary of a study protocol for a randomized controlled trial.评估人抗 SARS-CoV-2 恢复期血浆在 COVID-19 重症成人中的疗效和安全性：一项随机对照试验研究方案的结构化总结。
Trials. 2020 Jun 8;21(1):499. doi: 10.1186/s13063-020-04422-y.
4
Reconvalescent plasma/camostat mesylate in early SARS-CoV-2 Q-PCR positive high-risk individuals (RES-Q-HR): a structured summary of a study protocol for a randomized controlled trial.恢复期血浆/甲磺酸卡莫司他用于早期SARS-CoV-2 Q-PCR阳性高危个体（RES-Q-HR）：一项随机对照试验研究方案的结构化总结
Trials. 2021 May 17;22(1):343. doi: 10.1186/s13063-021-05181-0.
5
Randomized clinical trial to evaluate safety and efficacy of convalescent plasma use among hospitalized patients with COVID-19 (PERUCONPLASMA): a structured summary of a study protocol for a randomized controlled trial.随机临床试验评估 COVID-19 住院患者使用恢复期血浆的安全性和疗效（PERUCONPLASMA）：一项随机对照试验研究方案的结构化总结。
Trials. 2021 May 17;22(1):342. doi: 10.1186/s13063-021-05189-6.
6
Correction to: Treatment of severely ill COVID-19 patients with anti-interleukin drugs (COV-AID): A structured summary of a study protocol for a randomised controlled trial.对《使用抗白细胞介素药物治疗重症 COVID-19 患者（COV-AID）：一项随机对照试验研究方案的结构化总结》的更正
Trials. 2020 Jun 22;21(1):556. doi: 10.1186/s13063-020-04519-4.
7
A randomised, double-blind, placebo-controlled, pilot trial of intravenous plasma purified alpha-1 antitrypsin for SARS-CoV-2-induced Acute Respiratory Distress Syndrome: a structured summary of a study protocol for a randomised, controlled trial.静脉注射血浆纯化的α-1 抗胰蛋白酶治疗 SARS-CoV-2 诱导的急性呼吸窘迫综合征的随机、双盲、安慰剂对照、初步临床试验：一项随机对照试验研究方案的结构化总结。
Trials. 2021 Apr 19;22(1):288. doi: 10.1186/s13063-021-05254-0.
8
A Randomized Open label Phase-II Clinical Trial with or without Infusion of Plasma from Subjects after Convalescence of SARS-CoV-2 Infection in High-Risk Patients with Confirmed Severe SARS-CoV-2 Disease (RECOVER): A structured summary of a study protocol for a randomised controlled trial.一项针对高风险确诊严重 SARS-CoV-2 疾病患者的随机开放标签 II 期临床试验，比较 SARS-CoV-2 感染后恢复期患者输注血浆与未输注血浆的疗效（RECOVER）：一项随机对照试验的研究方案的结构化总结。
Trials. 2020 Oct 6;21(1):828. doi: 10.1186/s13063-020-04735-y.
9
A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.一项评估 SARS-CoV-2 疫苗（灭活，Vero 细胞）有效性和安全性的随机、双盲、安慰剂对照 III 期临床试验：一项随机对照试验研究方案的结构化总结。
Trials. 2021 Apr 13;22(1):276. doi: 10.1186/s13063-021-05180-1.
10
Convalescent plasma transfusion therapy in severe COVID-19 patients- a safety, efficacy and dose response study: A structured summary of a study protocol of a phase II randomized controlled trial.重症 COVID-19 患者恢复期血浆输血治疗——一项安全性、有效性和剂量反应研究：一项 II 期随机对照试验研究方案的结构化总结
Trials. 2020 Oct 26;21(1):883. doi: 10.1186/s13063-020-04734-z.

引用本文的文献

1
Convalescent plasma for people with COVID-19: a living systematic review.COVID-19 患者恢复期血浆治疗：一项实时系统评价。
Cochrane Database Syst Rev. 2023 May 10;5(5):CD013600. doi: 10.1002/14651858.CD013600.pub6.
2
Convalescent plasma for people with COVID-19: a living systematic review.COVID-19 患者恢复期血浆治疗：一项实时系统评价。
Cochrane Database Syst Rev. 2023 Feb 1;2(2):CD013600. doi: 10.1002/14651858.CD013600.pub5.
3
Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review.恢复期血浆或高免疫球蛋白用于 COVID-19 患者：一项实时系统评价。
Cochrane Database Syst Rev. 2021 May 20;5(5):CD013600. doi: 10.1002/14651858.CD013600.pub4.

本文引用的文献

1
Convalescent plasma treatment of severe COVID-19: a propensity score-matched control study.恢复期血浆治疗重症 COVID-19：一项倾向评分匹配对照研究。
Nat Med. 2020 Nov;26(11):1708-1713. doi: 10.1038/s41591-020-1088-9. Epub 2020 Sep 15.
2
Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: A structured summary of a study protocol for a randomized controlled trial.评估人抗 SARS-CoV-2 恢复期血浆在 COVID-19 重症成人中的疗效和安全性：一项随机对照试验研究方案的结构化总结。
Trials. 2020 Jun 8;21(1):499. doi: 10.1186/s13063-020-04422-y.
3
Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19: A Randomized Clinical Trial.恢复期血浆疗法对重症和危及生命的 COVID-19 患者临床改善时间的影响：一项随机临床试验。
JAMA. 2020 Aug 4;324(5):460-470. doi: 10.1001/jama.2020.10044.